Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Unpreserved latanoprost + timolol (T2347) vs Xalacom in glaucoma or ocular hypertension
2013-005222-29Phase 3Completed
- Sponsor
- Laboratoires Théa
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of latanoprost + timolol in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Laboratoires Théa. Primary endpoint: Change from baseline in mean intraocular pressure at Day 84 in worse eye (9:00 am). Started Jul 2014; status: completed.
02
Drugs
latanoprost + timolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2013-005222-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005222-29.